![conference banner](/images/conference-banner.jpeg)
Abstract
Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible importance of initiating as well as contributing factors such as reactive oxygen species and modified autoantigens. It is speculated that drug targets of factors important to disease pathogenesis may provide safe and effective adductive treatment to preserve beta cell function in autoantibody positive subjects who are at maximum risk for disease.
Keywords: variable number tandem repeat (VNTR), CTLA-4, Viral infections, Cadmium, Oxidative Stress, antioxidant
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease
Volume: 6 Issue: 1
Author(s): L. M. Bekris, T. J. Kavanagh and A. Lernmark
Affiliation:
Keywords: variable number tandem repeat (VNTR), CTLA-4, Viral infections, Cadmium, Oxidative Stress, antioxidant
Abstract: Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible importance of initiating as well as contributing factors such as reactive oxygen species and modified autoantigens. It is speculated that drug targets of factors important to disease pathogenesis may provide safe and effective adductive treatment to preserve beta cell function in autoantibody positive subjects who are at maximum risk for disease.
Export Options
About this article
Cite this article as:
Bekris M. L., Kavanagh J. T. and Lernmark A., Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2006; 6 (1) . https://dx.doi.org/10.2174/187153006776056576
DOI https://dx.doi.org/10.2174/187153006776056576 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy Time Trends and Gender Differences in Incidence and Prevalence of Type 1 Diabetes in Sweden
Current Diabetes Reviews Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Current Medicinal Chemistry “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Effect of Neuroinflammation on ABC Transporters: Possible Contribution to Refractory Epilepsy
CNS & Neurological Disorders - Drug Targets OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Erythropoietin and Oxidative Stress
Current Neurovascular Research Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Ischemic Brain Injury
Recent Patents on CNS Drug Discovery (Discontinued) Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Metabolomics Approach Reveals Altered Plasma Amino Acid and Sphingolipid Profiles Associated with Patholological State in Transition Dairy Cows
Current Metabolomics Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Immunomodulation of the Allergic Inflammatory Response: New Developments
Inflammation & Allergy - Drug Targets (Discontinued) Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets